Global Amyotrophic Lateral Sclerosis (ALS) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Amyotrophic Lateral Sclerosis (ALS) market size was valued at USD 308.7 million in 2023 and is forecast to a readjusted size of USD 366.6 million by 2030 with a CAGR of 2.5% during review period.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
The Global Info Research report includes an overview of the development of the Amyotrophic Lateral Sclerosis (ALS) industry chain, the market status of Hospital (Riluzole, Edaravone (Radicava)), Drugs Store (Riluzole, Edaravone (Radicava)), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Amyotrophic Lateral Sclerosis (ALS).
Regionally, the report analyzes the Amyotrophic Lateral Sclerosis (ALS) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Amyotrophic Lateral Sclerosis (ALS) market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Amyotrophic Lateral Sclerosis (ALS) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Amyotrophic Lateral Sclerosis (ALS) industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Unit), revenue generated, and market share of different by Type (e.g., Riluzole, Edaravone (Radicava)).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Amyotrophic Lateral Sclerosis (ALS) market.
Regional Analysis: The report involves examining the Amyotrophic Lateral Sclerosis (ALS) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Amyotrophic Lateral Sclerosis (ALS) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Amyotrophic Lateral Sclerosis (ALS):
Company Analysis: Report covers individual Amyotrophic Lateral Sclerosis (ALS) manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Amyotrophic Lateral Sclerosis (ALS) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Drugs Store).
Technology Analysis: Report covers specific technologies relevant to Amyotrophic Lateral Sclerosis (ALS). It assesses the current state, advancements, and potential future developments in Amyotrophic Lateral Sclerosis (ALS) areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Amyotrophic Lateral Sclerosis (ALS) market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Amyotrophic Lateral Sclerosis (ALS) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Chapter 1, to describe Amyotrophic Lateral Sclerosis (ALS) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Amyotrophic Lateral Sclerosis (ALS), with price, sales, revenue and global market share of Amyotrophic Lateral Sclerosis (ALS) from 2019 to 2024.
Chapter 3, the Amyotrophic Lateral Sclerosis (ALS) competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Amyotrophic Lateral Sclerosis (ALS) breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Amyotrophic Lateral Sclerosis (ALS) market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Amyotrophic Lateral Sclerosis (ALS).
Chapter 14 and 15, to describe Amyotrophic Lateral Sclerosis (ALS) sales channel, distributors, customers, research findings and conclusion.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
The Global Info Research report includes an overview of the development of the Amyotrophic Lateral Sclerosis (ALS) industry chain, the market status of Hospital (Riluzole, Edaravone (Radicava)), Drugs Store (Riluzole, Edaravone (Radicava)), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Amyotrophic Lateral Sclerosis (ALS).
Regionally, the report analyzes the Amyotrophic Lateral Sclerosis (ALS) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Amyotrophic Lateral Sclerosis (ALS) market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Amyotrophic Lateral Sclerosis (ALS) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Amyotrophic Lateral Sclerosis (ALS) industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Unit), revenue generated, and market share of different by Type (e.g., Riluzole, Edaravone (Radicava)).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Amyotrophic Lateral Sclerosis (ALS) market.
Regional Analysis: The report involves examining the Amyotrophic Lateral Sclerosis (ALS) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Amyotrophic Lateral Sclerosis (ALS) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Amyotrophic Lateral Sclerosis (ALS):
Company Analysis: Report covers individual Amyotrophic Lateral Sclerosis (ALS) manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Amyotrophic Lateral Sclerosis (ALS) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Drugs Store).
Technology Analysis: Report covers specific technologies relevant to Amyotrophic Lateral Sclerosis (ALS). It assesses the current state, advancements, and potential future developments in Amyotrophic Lateral Sclerosis (ALS) areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Amyotrophic Lateral Sclerosis (ALS) market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Amyotrophic Lateral Sclerosis (ALS) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- Riluzole
- Edaravone (Radicava)
- Other
- Hospital
- Drugs Store
- Other
- Mitsubishi Tanabe Pharma
- Sanofi
- Mylan Pharma
- Apotex
- Glemark Generics
- Covis Pharma
- Sun Pharma
- Lunan Pharma
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Amyotrophic Lateral Sclerosis (ALS) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Amyotrophic Lateral Sclerosis (ALS), with price, sales, revenue and global market share of Amyotrophic Lateral Sclerosis (ALS) from 2019 to 2024.
Chapter 3, the Amyotrophic Lateral Sclerosis (ALS) competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Amyotrophic Lateral Sclerosis (ALS) breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Amyotrophic Lateral Sclerosis (ALS) market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Amyotrophic Lateral Sclerosis (ALS).
Chapter 14 and 15, to describe Amyotrophic Lateral Sclerosis (ALS) sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Amyotrophic Lateral Sclerosis (ALS)
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Riluzole
1.3.3 Edaravone (Radicava)
1.3.4 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Drugs Store
1.4.4 Other
1.5 Global Amyotrophic Lateral Sclerosis (ALS) Market Size & Forecast
1.5.1 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (2019-2030)
1.5.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Mitsubishi Tanabe Pharma
2.1.1 Mitsubishi Tanabe Pharma Details
2.1.2 Mitsubishi Tanabe Pharma Major Business
2.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
2.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Mitsubishi Tanabe Pharma Recent Developments/Updates
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Product and Services
2.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Sanofi Recent Developments/Updates
2.3 Mylan Pharma
2.3.1 Mylan Pharma Details
2.3.2 Mylan Pharma Major Business
2.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
2.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Mylan Pharma Recent Developments/Updates
2.4 Apotex
2.4.1 Apotex Details
2.4.2 Apotex Major Business
2.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Product and Services
2.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Apotex Recent Developments/Updates
2.5 Glemark Generics
2.5.1 Glemark Generics Details
2.5.2 Glemark Generics Major Business
2.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product and Services
2.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Glemark Generics Recent Developments/Updates
2.6 Covis Pharma
2.6.1 Covis Pharma Details
2.6.2 Covis Pharma Major Business
2.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
2.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Covis Pharma Recent Developments/Updates
2.7 Sun Pharma
2.7.1 Sun Pharma Details
2.7.2 Sun Pharma Major Business
2.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
2.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Sun Pharma Recent Developments/Updates
2.8 Lunan Pharma
2.8.1 Lunan Pharma Details
2.8.2 Lunan Pharma Major Business
2.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
2.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Lunan Pharma Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY MANUFACTURER
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Manufacturer (2019-2024)
3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Manufacturer (2019-2024)
3.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Amyotrophic Lateral Sclerosis (ALS) by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Amyotrophic Lateral Sclerosis (ALS) Manufacturer Market Share in 2023
3.4.2 Top 6 Amyotrophic Lateral Sclerosis (ALS) Manufacturer Market Share in 2023
3.5 Amyotrophic Lateral Sclerosis (ALS) Market: Overall Company Footprint Analysis
3.5.1 Amyotrophic Lateral Sclerosis (ALS) Market: Region Footprint
3.5.2 Amyotrophic Lateral Sclerosis (ALS) Market: Company Product Type Footprint
3.5.3 Amyotrophic Lateral Sclerosis (ALS) Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size by Region
4.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2019-2030)
4.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2019-2030)
4.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Region (2019-2030)
4.2 North America Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030)
4.3 Europe Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030)
4.4 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030)
4.5 South America Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030)
4.6 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
5.2 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Type (2019-2030)
5.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
6.2 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Application (2019-2030)
6.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
7.2 North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
7.3 North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
7.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2030)
7.3.2 North America Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
8.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
8.3 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
8.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2030)
8.3.2 Europe Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size by Region
9.3.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
10.2 South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
10.3 South America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
10.3.1 South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2030)
10.3.2 South America Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
11.3.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Amyotrophic Lateral Sclerosis (ALS) Market Drivers
12.2 Amyotrophic Lateral Sclerosis (ALS) Market Restraints
12.3 Amyotrophic Lateral Sclerosis (ALS) Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Amyotrophic Lateral Sclerosis (ALS) and Key Manufacturers
13.2 Manufacturing Costs Percentage of Amyotrophic Lateral Sclerosis (ALS)
13.3 Amyotrophic Lateral Sclerosis (ALS) Production Process
13.4 Amyotrophic Lateral Sclerosis (ALS) Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Amyotrophic Lateral Sclerosis (ALS) Typical Distributors
14.3 Amyotrophic Lateral Sclerosis (ALS) Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Amyotrophic Lateral Sclerosis (ALS)
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Riluzole
1.3.3 Edaravone (Radicava)
1.3.4 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Drugs Store
1.4.4 Other
1.5 Global Amyotrophic Lateral Sclerosis (ALS) Market Size & Forecast
1.5.1 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (2019-2030)
1.5.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Mitsubishi Tanabe Pharma
2.1.1 Mitsubishi Tanabe Pharma Details
2.1.2 Mitsubishi Tanabe Pharma Major Business
2.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
2.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Mitsubishi Tanabe Pharma Recent Developments/Updates
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Product and Services
2.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Sanofi Recent Developments/Updates
2.3 Mylan Pharma
2.3.1 Mylan Pharma Details
2.3.2 Mylan Pharma Major Business
2.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
2.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Mylan Pharma Recent Developments/Updates
2.4 Apotex
2.4.1 Apotex Details
2.4.2 Apotex Major Business
2.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Product and Services
2.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Apotex Recent Developments/Updates
2.5 Glemark Generics
2.5.1 Glemark Generics Details
2.5.2 Glemark Generics Major Business
2.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product and Services
2.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Glemark Generics Recent Developments/Updates
2.6 Covis Pharma
2.6.1 Covis Pharma Details
2.6.2 Covis Pharma Major Business
2.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
2.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Covis Pharma Recent Developments/Updates
2.7 Sun Pharma
2.7.1 Sun Pharma Details
2.7.2 Sun Pharma Major Business
2.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
2.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Sun Pharma Recent Developments/Updates
2.8 Lunan Pharma
2.8.1 Lunan Pharma Details
2.8.2 Lunan Pharma Major Business
2.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
2.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Lunan Pharma Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY MANUFACTURER
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Manufacturer (2019-2024)
3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Manufacturer (2019-2024)
3.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Amyotrophic Lateral Sclerosis (ALS) by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Amyotrophic Lateral Sclerosis (ALS) Manufacturer Market Share in 2023
3.4.2 Top 6 Amyotrophic Lateral Sclerosis (ALS) Manufacturer Market Share in 2023
3.5 Amyotrophic Lateral Sclerosis (ALS) Market: Overall Company Footprint Analysis
3.5.1 Amyotrophic Lateral Sclerosis (ALS) Market: Region Footprint
3.5.2 Amyotrophic Lateral Sclerosis (ALS) Market: Company Product Type Footprint
3.5.3 Amyotrophic Lateral Sclerosis (ALS) Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size by Region
4.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2019-2030)
4.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2019-2030)
4.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Region (2019-2030)
4.2 North America Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030)
4.3 Europe Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030)
4.4 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030)
4.5 South America Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030)
4.6 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
5.2 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Type (2019-2030)
5.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
6.2 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Application (2019-2030)
6.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
7.2 North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
7.3 North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
7.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2030)
7.3.2 North America Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
8.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
8.3 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
8.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2030)
8.3.2 Europe Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size by Region
9.3.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
10.2 South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
10.3 South America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
10.3.1 South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2030)
10.3.2 South America Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
11.3.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Amyotrophic Lateral Sclerosis (ALS) Market Drivers
12.2 Amyotrophic Lateral Sclerosis (ALS) Market Restraints
12.3 Amyotrophic Lateral Sclerosis (ALS) Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Amyotrophic Lateral Sclerosis (ALS) and Key Manufacturers
13.2 Manufacturing Costs Percentage of Amyotrophic Lateral Sclerosis (ALS)
13.3 Amyotrophic Lateral Sclerosis (ALS) Production Process
13.4 Amyotrophic Lateral Sclerosis (ALS) Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Amyotrophic Lateral Sclerosis (ALS) Typical Distributors
14.3 Amyotrophic Lateral Sclerosis (ALS) Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Mitsubishi Tanabe Pharma Basic Information, Manufacturing Base and Competitors
Table 4. Mitsubishi Tanabe Pharma Major Business
Table 5. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 6. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Mitsubishi Tanabe Pharma Recent Developments/Updates
Table 8. Sanofi Basic Information, Manufacturing Base and Competitors
Table 9. Sanofi Major Business
Table 10. Sanofi Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 11. Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Sanofi Recent Developments/Updates
Table 13. Mylan Pharma Basic Information, Manufacturing Base and Competitors
Table 14. Mylan Pharma Major Business
Table 15. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 16. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Mylan Pharma Recent Developments/Updates
Table 18. Apotex Basic Information, Manufacturing Base and Competitors
Table 19. Apotex Major Business
Table 20. Apotex Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 21. Apotex Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Apotex Recent Developments/Updates
Table 23. Glemark Generics Basic Information, Manufacturing Base and Competitors
Table 24. Glemark Generics Major Business
Table 25. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 26. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Glemark Generics Recent Developments/Updates
Table 28. Covis Pharma Basic Information, Manufacturing Base and Competitors
Table 29. Covis Pharma Major Business
Table 30. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 31. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Covis Pharma Recent Developments/Updates
Table 33. Sun Pharma Basic Information, Manufacturing Base and Competitors
Table 34. Sun Pharma Major Business
Table 35. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 36. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Sun Pharma Recent Developments/Updates
Table 38. Lunan Pharma Basic Information, Manufacturing Base and Competitors
Table 39. Lunan Pharma Major Business
Table 40. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 41. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Lunan Pharma Recent Developments/Updates
Table 43. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Manufacturer (2019-2024) & (K Unit)
Table 44. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Manufacturer (2019-2024) & (USD Million)
Table 45. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Manufacturer (2019-2024) & (USD/Unit)
Table 46. Market Position of Manufacturers in Amyotrophic Lateral Sclerosis (ALS), (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 47. Head Office and Amyotrophic Lateral Sclerosis (ALS) Production Site of Key Manufacturer
Table 48. Amyotrophic Lateral Sclerosis (ALS) Market: Company Product Type Footprint
Table 49. Amyotrophic Lateral Sclerosis (ALS) Market: Company Product Application Footprint
Table 50. Amyotrophic Lateral Sclerosis (ALS) New Market Entrants and Barriers to Market Entry
Table 51. Amyotrophic Lateral Sclerosis (ALS) Mergers, Acquisition, Agreements, and Collaborations
Table 52. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2019-2024) & (K Unit)
Table 53. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2025-2030) & (K Unit)
Table 54. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2019-2024) & (USD Million)
Table 55. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2025-2030) & (USD Million)
Table 56. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Region (2019-2024) & (USD/Unit)
Table 57. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Region (2025-2030) & (USD/Unit)
Table 58. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2024) & (K Unit)
Table 59. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2025-2030) & (K Unit)
Table 60. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Type (2019-2024) & (USD Million)
Table 61. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Type (2025-2030) & (USD Million)
Table 62. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Type (2019-2024) & (USD/Unit)
Table 63. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Type (2025-2030) & (USD/Unit)
Table 64. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2024) & (K Unit)
Table 65. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2025-2030) & (K Unit)
Table 66. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Application (2019-2024) & (USD Million)
Table 67. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Application (2025-2030) & (USD Million)
Table 68. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Application (2019-2024) & (USD/Unit)
Table 69. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Application (2025-2030) & (USD/Unit)
Table 70. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2024) & (K Unit)
Table 71. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2025-2030) & (K Unit)
Table 72. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2024) & (K Unit)
Table 73. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2025-2030) & (K Unit)
Table 74. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2024) & (K Unit)
Table 75. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2025-2030) & (K Unit)
Table 76. North America Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2024) & (USD Million)
Table 77. North America Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2025-2030) & (USD Million)
Table 78. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2024) & (K Unit)
Table 79. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2025-2030) & (K Unit)
Table 80. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2024) & (K Unit)
Table 81. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2025-2030) & (K Unit)
Table 82. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2024) & (K Unit)
Table 83. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2025-2030) & (K Unit)
Table 84. Europe Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2024) & (USD Million)
Table 85. Europe Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2025-2030) & (USD Million)
Table 86. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2024) & (K Unit)
Table 87. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2025-2030) & (K Unit)
Table 88. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2024) & (K Unit)
Table 89. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2025-2030) & (K Unit)
Table 90. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2019-2024) & (K Unit)
Table 91. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2025-2030) & (K Unit)
Table 92. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2019-2024) & (USD Million)
Table 93. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2025-2030) & (USD Million)
Table 94. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2024) & (K Unit)
Table 95. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2025-2030) & (K Unit)
Table 96. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2024) & (K Unit)
Table 97. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2025-2030) & (K Unit)
Table 98. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2024) & (K Unit)
Table 99. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2025-2030) & (K Unit)
Table 100. South America Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2024) & (USD Million)
Table 101. South America Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2025-2030) & (USD Million)
Table 102. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2024) & (K Unit)
Table 103. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2025-2030) & (K Unit)
Table 104. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2024) & (K Unit)
Table 105. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2025-2030) & (K Unit)
Table 106. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2019-2024) & (K Unit)
Table 107. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2025-2030) & (K Unit)
Table 108. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2019-2024) & (USD Million)
Table 109. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2025-2030) & (USD Million)
Table 110. Amyotrophic Lateral Sclerosis (ALS) Raw Material
Table 111. Key Manufacturers of Amyotrophic Lateral Sclerosis (ALS) Raw Materials
Table 112. Amyotrophic Lateral Sclerosis (ALS) Typical Distributors
Table 113. Amyotrophic Lateral Sclerosis (ALS) Typical Customers
Table 1. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Mitsubishi Tanabe Pharma Basic Information, Manufacturing Base and Competitors
Table 4. Mitsubishi Tanabe Pharma Major Business
Table 5. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 6. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Mitsubishi Tanabe Pharma Recent Developments/Updates
Table 8. Sanofi Basic Information, Manufacturing Base and Competitors
Table 9. Sanofi Major Business
Table 10. Sanofi Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 11. Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Sanofi Recent Developments/Updates
Table 13. Mylan Pharma Basic Information, Manufacturing Base and Competitors
Table 14. Mylan Pharma Major Business
Table 15. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 16. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Mylan Pharma Recent Developments/Updates
Table 18. Apotex Basic Information, Manufacturing Base and Competitors
Table 19. Apotex Major Business
Table 20. Apotex Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 21. Apotex Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Apotex Recent Developments/Updates
Table 23. Glemark Generics Basic Information, Manufacturing Base and Competitors
Table 24. Glemark Generics Major Business
Table 25. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 26. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Glemark Generics Recent Developments/Updates
Table 28. Covis Pharma Basic Information, Manufacturing Base and Competitors
Table 29. Covis Pharma Major Business
Table 30. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 31. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Covis Pharma Recent Developments/Updates
Table 33. Sun Pharma Basic Information, Manufacturing Base and Competitors
Table 34. Sun Pharma Major Business
Table 35. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 36. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Sun Pharma Recent Developments/Updates
Table 38. Lunan Pharma Basic Information, Manufacturing Base and Competitors
Table 39. Lunan Pharma Major Business
Table 40. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
Table 41. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (K Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Lunan Pharma Recent Developments/Updates
Table 43. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Manufacturer (2019-2024) & (K Unit)
Table 44. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Manufacturer (2019-2024) & (USD Million)
Table 45. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Manufacturer (2019-2024) & (USD/Unit)
Table 46. Market Position of Manufacturers in Amyotrophic Lateral Sclerosis (ALS), (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 47. Head Office and Amyotrophic Lateral Sclerosis (ALS) Production Site of Key Manufacturer
Table 48. Amyotrophic Lateral Sclerosis (ALS) Market: Company Product Type Footprint
Table 49. Amyotrophic Lateral Sclerosis (ALS) Market: Company Product Application Footprint
Table 50. Amyotrophic Lateral Sclerosis (ALS) New Market Entrants and Barriers to Market Entry
Table 51. Amyotrophic Lateral Sclerosis (ALS) Mergers, Acquisition, Agreements, and Collaborations
Table 52. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2019-2024) & (K Unit)
Table 53. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2025-2030) & (K Unit)
Table 54. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2019-2024) & (USD Million)
Table 55. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2025-2030) & (USD Million)
Table 56. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Region (2019-2024) & (USD/Unit)
Table 57. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Region (2025-2030) & (USD/Unit)
Table 58. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2024) & (K Unit)
Table 59. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2025-2030) & (K Unit)
Table 60. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Type (2019-2024) & (USD Million)
Table 61. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Type (2025-2030) & (USD Million)
Table 62. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Type (2019-2024) & (USD/Unit)
Table 63. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Type (2025-2030) & (USD/Unit)
Table 64. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2024) & (K Unit)
Table 65. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2025-2030) & (K Unit)
Table 66. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Application (2019-2024) & (USD Million)
Table 67. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Application (2025-2030) & (USD Million)
Table 68. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Application (2019-2024) & (USD/Unit)
Table 69. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Application (2025-2030) & (USD/Unit)
Table 70. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2024) & (K Unit)
Table 71. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2025-2030) & (K Unit)
Table 72. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2024) & (K Unit)
Table 73. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2025-2030) & (K Unit)
Table 74. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2024) & (K Unit)
Table 75. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2025-2030) & (K Unit)
Table 76. North America Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2024) & (USD Million)
Table 77. North America Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2025-2030) & (USD Million)
Table 78. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2024) & (K Unit)
Table 79. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2025-2030) & (K Unit)
Table 80. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2024) & (K Unit)
Table 81. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2025-2030) & (K Unit)
Table 82. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2024) & (K Unit)
Table 83. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2025-2030) & (K Unit)
Table 84. Europe Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2024) & (USD Million)
Table 85. Europe Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2025-2030) & (USD Million)
Table 86. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2024) & (K Unit)
Table 87. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2025-2030) & (K Unit)
Table 88. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2024) & (K Unit)
Table 89. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2025-2030) & (K Unit)
Table 90. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2019-2024) & (K Unit)
Table 91. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2025-2030) & (K Unit)
Table 92. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2019-2024) & (USD Million)
Table 93. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2025-2030) & (USD Million)
Table 94. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2024) & (K Unit)
Table 95. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2025-2030) & (K Unit)
Table 96. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2024) & (K Unit)
Table 97. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2025-2030) & (K Unit)
Table 98. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2024) & (K Unit)
Table 99. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2025-2030) & (K Unit)
Table 100. South America Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2024) & (USD Million)
Table 101. South America Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2025-2030) & (USD Million)
Table 102. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2024) & (K Unit)
Table 103. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2025-2030) & (K Unit)
Table 104. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2024) & (K Unit)
Table 105. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2025-2030) & (K Unit)
Table 106. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2019-2024) & (K Unit)
Table 107. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2025-2030) & (K Unit)
Table 108. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2019-2024) & (USD Million)
Table 109. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2025-2030) & (USD Million)
Table 110. Amyotrophic Lateral Sclerosis (ALS) Raw Material
Table 111. Key Manufacturers of Amyotrophic Lateral Sclerosis (ALS) Raw Materials
Table 112. Amyotrophic Lateral Sclerosis (ALS) Typical Distributors
Table 113. Amyotrophic Lateral Sclerosis (ALS) Typical Customers
LIST OF FIGURES
Figure 1. Amyotrophic Lateral Sclerosis (ALS) Picture
Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Type in 2023
Figure 4. Riluzole Examples
Figure 5. Edaravone (Radicava) Examples
Figure 6. Other Examples
Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 8. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Application in 2023
Figure 9. Hospital Examples
Figure 10. Drugs Store Examples
Figure 11. Other Examples
Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (2019-2030) & (K Unit)
Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Average Price (2019-2030) & (USD/Unit)
Figure 16. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Manufacturer in 2023
Figure 17. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Manufacturer in 2023
Figure 18. Producer Shipments of Amyotrophic Lateral Sclerosis (ALS) by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 19. Top 3 Amyotrophic Lateral Sclerosis (ALS) Manufacturer (Consumption Value) Market Share in 2023
Figure 20. Top 6 Amyotrophic Lateral Sclerosis (ALS) Manufacturer (Consumption Value) Market Share in 2023
Figure 21. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Region (2019-2030)
Figure 22. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Region (2019-2030)
Figure 23. North America Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030) & (USD Million)
Figure 24. Europe Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030) & (USD Million)
Figure 25. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030) & (USD Million)
Figure 26. South America Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030) & (USD Million)
Figure 27. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030) & (USD Million)
Figure 28. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2019-2030)
Figure 29. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Type (2019-2030)
Figure 30. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Type (2019-2030) & (USD/Unit)
Figure 31. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2019-2030)
Figure 32. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Application (2019-2030)
Figure 33. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Application (2019-2030) & (USD/Unit)
Figure 34. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2019-2030)
Figure 35. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2019-2030)
Figure 36. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Country (2019-2030)
Figure 37. North America Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Country (2019-2030)
Figure 38. United States Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 39. Canada Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Mexico Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 41. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2019-2030)
Figure 42. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2019-2030)
Figure 43. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Country (2019-2030)
Figure 44. Europe Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Country (2019-2030)
Figure 45. Germany Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 46. France Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. United Kingdom Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. Russia Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Italy Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2019-2030)
Figure 51. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2019-2030)
Figure 52. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Region (2019-2030)
Figure 53. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Region (2019-2030)
Figure 54. China Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 55. Japan Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Korea Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. India Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Australia Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2019-2030)
Figure 61. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2019-2030)
Figure 62. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Country (2019-2030)
Figure 63. South America Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Country (2019-2030)
Figure 64. Brazil Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 65. Argentina Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 66. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2019-2030)
Figure 67. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2019-2030)
Figure 68. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Region (2019-2030)
Figure 69. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Region (2019-2030)
Figure 70. Turkey Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 71. Egypt Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. South Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. Amyotrophic Lateral Sclerosis (ALS) Market Drivers
Figure 75. Amyotrophic Lateral Sclerosis (ALS) Market Restraints
Figure 76. Amyotrophic Lateral Sclerosis (ALS) Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Amyotrophic Lateral Sclerosis (ALS) in 2023
Figure 79. Manufacturing Process Analysis of Amyotrophic Lateral Sclerosis (ALS)
Figure 80. Amyotrophic Lateral Sclerosis (ALS) Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
Figure 1. Amyotrophic Lateral Sclerosis (ALS) Picture
Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Type in 2023
Figure 4. Riluzole Examples
Figure 5. Edaravone (Radicava) Examples
Figure 6. Other Examples
Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 8. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Application in 2023
Figure 9. Hospital Examples
Figure 10. Drugs Store Examples
Figure 11. Other Examples
Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (2019-2030) & (K Unit)
Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Average Price (2019-2030) & (USD/Unit)
Figure 16. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Manufacturer in 2023
Figure 17. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Manufacturer in 2023
Figure 18. Producer Shipments of Amyotrophic Lateral Sclerosis (ALS) by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 19. Top 3 Amyotrophic Lateral Sclerosis (ALS) Manufacturer (Consumption Value) Market Share in 2023
Figure 20. Top 6 Amyotrophic Lateral Sclerosis (ALS) Manufacturer (Consumption Value) Market Share in 2023
Figure 21. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Region (2019-2030)
Figure 22. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Region (2019-2030)
Figure 23. North America Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030) & (USD Million)
Figure 24. Europe Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030) & (USD Million)
Figure 25. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030) & (USD Million)
Figure 26. South America Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030) & (USD Million)
Figure 27. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030) & (USD Million)
Figure 28. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2019-2030)
Figure 29. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Type (2019-2030)
Figure 30. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Type (2019-2030) & (USD/Unit)
Figure 31. Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2019-2030)
Figure 32. Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Application (2019-2030)
Figure 33. Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Application (2019-2030) & (USD/Unit)
Figure 34. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2019-2030)
Figure 35. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2019-2030)
Figure 36. North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Country (2019-2030)
Figure 37. North America Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Country (2019-2030)
Figure 38. United States Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 39. Canada Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Mexico Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 41. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2019-2030)
Figure 42. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2019-2030)
Figure 43. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Country (2019-2030)
Figure 44. Europe Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Country (2019-2030)
Figure 45. Germany Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 46. France Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. United Kingdom Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. Russia Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Italy Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2019-2030)
Figure 51. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2019-2030)
Figure 52. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Region (2019-2030)
Figure 53. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Region (2019-2030)
Figure 54. China Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 55. Japan Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Korea Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. India Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Australia Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2019-2030)
Figure 61. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2019-2030)
Figure 62. South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Country (2019-2030)
Figure 63. South America Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Country (2019-2030)
Figure 64. Brazil Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 65. Argentina Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 66. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Type (2019-2030)
Figure 67. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Application (2019-2030)
Figure 68. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity Market Share by Region (2019-2030)
Figure 69. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Value Market Share by Region (2019-2030)
Figure 70. Turkey Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 71. Egypt Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. South Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. Amyotrophic Lateral Sclerosis (ALS) Market Drivers
Figure 75. Amyotrophic Lateral Sclerosis (ALS) Market Restraints
Figure 76. Amyotrophic Lateral Sclerosis (ALS) Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Amyotrophic Lateral Sclerosis (ALS) in 2023
Figure 79. Manufacturing Process Analysis of Amyotrophic Lateral Sclerosis (ALS)
Figure 80. Amyotrophic Lateral Sclerosis (ALS) Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
More Publications
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2026 by Company, Regions, Type and Application, Forecast to 2032
US$ 3,480.00
June 2026
84 pages
Global Amyotrophic Lateral Sclerosis Therapeutics Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
US$ 3,480.00
January 2019
124 pages
